|
IMAGING
Prediction
of Organ-Confined Prostate Cancer: Incremental Value of MR Imaging and
MR Spectroscopic Imaging to Staging Nomograms
Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York,
NY, USA
Radiology. 2006; 238: 597-603
- Purpose:
To assess retrospectively the incremental value of endorectal coil magnetic
resonance (MR) imaging and combined endorectal MR imaging-MR spectroscopic
imaging to the staging nomograms for predicting organ-confined prostate
cancer (OCPC).
-
Materials and Methods:
The institutional review board approved this HIPAA-compliant study and
issued a waiver of informed consent for review of the MR reports and
clinical data. Between November 1, 1999, and November 1, 2004, 229 patients
underwent endorectal MR imaging and 383 underwent combined endorectal
MR imaging-MR spectroscopic imaging before radical prostatectomy. Mean
patient age was 58 years (range, 32-74 years). MR studies were interpreted
prospectively by 12 radiologists who were informed of patients’
clinical data. On the basis of the MR reports, the risks of extracapsular
extension, seminal vesicle invasion, and lymph node metastasis were
scored retrospectively from 1 to 5; the highest score was subtracted
from 6 to determine a score (from 1 to 5) for the likelihood of OCPC
on MR studies. The staging nomograms were used to calculate the likelihood
of OCPC on the basis of serum prostate-specific antigen level, Gleason
grade at biopsy, and clinical stage. Histopathologic findings constituted
the reference standard. Logistic regression was used to estimate the
multivariable relations between OCPC and MR findings. The area under
the receiver operator characteristic curve was calculated for each model.
The jackknife method was used for bias correction.
-
Results:
MR findings contributed significant incremental value (P </= .02)
to the nomograms in the overall study population. The contribution of
MR findings was significant in all risk groups but was greatest in the
intermediate- and high-risk groups (P < .01 for both). Accuracy in
the prediction of OCPC with MR was higher when MR spectroscopic imaging
was used, but the difference was not significant.
-
Conclusion:
Endorectal MR imaging and combined endorectal MR imaging-MR spectroscopic
imaging contribute significant incremental value to the staging nomograms
in predicting OCPC.
- Editorial
Comment
Following strict criteria of macroscopic disease, endorectal MR imaging
associated with superficial phased array coil, allows an overall accuracy
of 83% and specificity of 98 % for detecting extraprostatic disease.
In this very well designed study 383 patients underwent endorectal MR
imaging combined with MR spectroscopic imaging, and 229 underwent endorectal
MR imaging alone. Mean patient age was 58 years (range, 32–74
years). None of the patients received neoadjuvant hormonal or radiation
therapy prior to surgery. Pathological diagnosis of prostate cancer
was made at biopsy in all patients. Clinical stage (determined by means
of digital rectal examination), serum PSA level, and Gleason grade in
the biopsy specimen, as well as MR data, were recorded retrospectively
from the patients’ medical records by two coauthors. Overall,
in the prediction of OCPC, the area under the ROC curve for the staging
nomograms was 0.80, while the area under the ROC curve for the staging
nomograms plus MR findings was 0.88; the difference was significant
(P < .01). The incremental value of MR findings to the staging nomograms
was significant in all three risk groups, although it was greater in
the intermediate- and high-risk groups (P < .01 for both) than in
the low-risk group (P = .02). In the combined endorectal MR imaging–MR
spectroscopic imaging group, the areas under the ROC curves were 0.81
for the staging nomograms and 0.90 for the staging nomograms plus MR
findings; the difference was significant (P < .01). The authors nicely
show that, the addition of MR findings to the “ Partin Tables”
(2001 version), significantly improved the prediction of OCPC for the
overall patient population (P < .01).
Additional advantages of MR imaging combined with MR spectroscopy is
the ability of these imaging methods to predict the risk of positive
surgical margins, demonstrate the exact site of extraprostatic extension
and to improve the surgeon’s decision to preserve or to resect
the neurovascular bundle during radical prostatectomy. Based on our
limited experience, using routinely combined endorectal MR imaging with
MR spectroscopy for staging prostatic cancer, in the last 16 months,
we agree with the authors conclusion. Endorectal MR imaging should be
included into future staging nomograms for the prediction of OCPC particularly
in those patients with intermediate and high risk for presenting extraprostatic
disease. Obviously further multicenter confirmatory studies are still
mandatory.
Dr.
Adilson Prando
Chief, Department of Radiology
Vera Cruz Hospital
Campinas, São Paulo, Brazil |